当前位置：
X-MOL 学术
›
Antivir. Res.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Recombinant pseudorabies virus expressing E2 of classical swine fever virus (CSFV) protects against both virulent pseudorabies virus and CSFV.
Antiviral Research ( IF 4.5 ) Pub Date : 2019-11-18 , DOI: 10.1016/j.antiviral.2019.104652 Wu Tong 1 , Hao Zheng 2 , Guo-Xin Li 2 , Fei Gao 2 , Tong-Ling Shan 2 , Yan-Jun Zhou 2 , Hai Yu 2 , Yi-Feng Jiang 2 , Ling-Xue Yu 2 , Li-Wei Li 2 , Ning Kong 2 , Guang-Zhi Tong 3 , Ji-Chang Li 4
Antiviral Research ( IF 4.5 ) Pub Date : 2019-11-18 , DOI: 10.1016/j.antiviral.2019.104652 Wu Tong 1 , Hao Zheng 2 , Guo-Xin Li 2 , Fei Gao 2 , Tong-Ling Shan 2 , Yan-Jun Zhou 2 , Hai Yu 2 , Yi-Feng Jiang 2 , Ling-Xue Yu 2 , Li-Wei Li 2 , Ning Kong 2 , Guang-Zhi Tong 3 , Ji-Chang Li 4
Affiliation
Both classical swine fever (CSF) and pseudorabies are highly contagious, economically significant diseases of swine in China. Although vaccination with the C-strain against classical swine fever virus (CSFV) is widely carried out and severe outbreaks of CSF seldom occur in China, CSF is sporadic in many pig herds and novel sub-subgenotypes of CSFV endlessly emerge. Thus, new measures are needed to eradicate CSFV from Chinese farms. The emergence of a pseudorabies virus (PRV) variant also posed a new challenge for the control of swine pseudorabies. Here, the recombinant PRV strain JS-2012-ΔgE/gI-E2 expressing E2 protein of CSFV was developed by inserting the E2 expression cassette into the intergenic region between the gG and gD genes of the gE/gI-deletion PRV variant strain JS-2012-ΔgE/gI. The recombinant virus was stable when passaged in vitro. A single vaccination of JS-2012-ΔgE/gI-E2 via intramuscular injection fully protected against lethal challenges of PRV and CSFV. Vaccination of piglets with the recombinant JS-2012-ΔgE/gI-E2 in the presence of high levels of maternally derived antibodies (Abs) to PRV can provide partial protection against lethal challenge of CSFV. Vaccination of the recombinant PRV JS-2012-ΔgE/gI-E2 strain did not induce the production of Abs to the gE protein of PRV or to the CSFV proteins other than E2. Thus, JS-2012-ΔgE/gI-E2 appears to be a promising recombinant marker vaccine candidate against PRV and CSFV for the control and eradication of the PRV variant and CSFV.
更新日期：2019-11-18
京公网安备 11010802027423号